David Quinn, MD
Medical Oncology · Los Angeles, CANPI 1043249584
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2020 at $52,227 and has fallen 100.0% since, to $26 in 2025.
Across 137 payments — averaging $977.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$28K
- Pfizer$25K
- Merck$22K
- Seagen Inc.$13K
- Exelixis Inc.$11K
- Genentech, Inc.$8K
- plus $26K from 14 others
Across 541 payments — averaging $7085.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
- Merck$1.2M
- Seagen Inc.$201K
- Pharmacyclics LLC, An Abbvie Company$183K
- Puma Biotechnology, Inc.$116K
- Bayer$105K
- plus $217K from 9 others
What the payments were for
- Consulting fees$79,30559%
- Speaking & faculty fees$35,38026%
- Travel & lodging$15,31111%
- Food & beverage$3,9043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 6 | $28,493 |
| Pfizer | 24 | $25,313 |
| Merck | 39 | $22,446 |
| Seagen Inc. | 12 | $13,032 |
| Exelixis Inc. | 11 | $10,612 |
| Genentech, Inc. | 7 | $7,637 |
| AstraZeneca | 13 | $4,459 |
| Advanced Accelerator Applications | 4 | $4,046 |
| F. Hoffmann-la Roche AG | 2 | $3,375 |
| Bristol Myers Squibb | 2 | $3,110 |
| EMD Serono, Inc. | 1 | $2,500 |
| Johnson & Johnson | 5 | $2,415 |
| AVEO Pharmaceuticals, Inc. | 1 | $2,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,625 |
| Astellas Pharma Global Development | 1 | $1,500 |
| Astellas Pharma US Inc | 3 | $1,112 |
| Myovant Sciences Inc. | 1 | $101 |
| Genentech USA, Inc. | 2 | $76 |
| Edwards Lifesciences | 1 | $26 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$133,901 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.